Suppr超能文献

比较 12 种肌少症定义在大型欧洲多国社区居住老年人群中的流行率。

Comparing Prevalence of Sarcopenia Using Twelve Sarcopenia Definitions in a Large Multinational European Population of Community-Dwelling Older Adults.

机构信息

Anna K. Stuck, Dr. med., Centre on Aging and Mobility, University Hospital Zurich and University of Zurich, c/o Stadtspital Waid, Tièchestrasse 99, 8037 Zürich

出版信息

J Nutr Health Aging. 2023;27(3):205-212. doi: 10.1007/s12603-023-1888-y.

Abstract

OBJECTIVES

Multinational prevalence data on sarcopenia among generally healthy older adults is limited. The aim of the study was to assess prevalence of sarcopenia in the DO-HEALTH European trial based on twelve current sarcopenia definitions.

SETTING AND PARTICIPANTS

This is an analysis of the DO-HEALTH study including 1495 of 2157 community-dwelling participants age 70+ years from Germany, France, Portugal, and Switzerland with complete measurements of the sarcopenia toolbox including muscle mass by DXA, grip strength, and gait speed.

MEASUREMENTS

The twelve sarcopenia definitions applied were Asian Working Group on Sarcopenia (AWGS1), AWGS2, Baumgartner, Delmonico, European Working Group on Sarcopenia in Older People (EWGSOP1), EWGSOP2, EWGSOP2-lower extremities, Foundation for the National Institutes of Health (FNIH1), FNIH2, International Working Group on Sarcopenia in Older People (IWGS), Morley, and Sarcopenia Definitions and Outcomes Consortium (SDOC).

RESULTS

Mean age was 74.9 years (SD 4.4); 63.3% were women. Sarcopenia prevalence ranged between 0.7% using the EWGSOP2 or AWGS2 definition, up to 16.8% using the Delmonico definition. Overall, most sarcopenia definitions, including Delmonico (16.8%), Baumgartner (12.8%), FNIH1(10.5%), IWGS (3.6%), EWGSOP1 (3.4%), SDOC (2.0%), Morley (1.3%), and AWGS1 (1.1%) tended to be higher than the prevalence based on EWGSOP2 (0.7%). In contrast, the definitions AWGS2 (0.7%), EWGSOP2-LE (1.1%), FNIH2 (1.0%) - all based on muscle mass and muscle strength - showed similar lower prevalence as EWGSOP2 (0.7%). Moreover, most sarcopenia definitions did not overlap on identifying sarcopenia on an individual participant-level.

CONCLUSION

In this multinational European trial of community-dwelling older adults we found major discordances of sarcopenia prevalence both on a population- and on a participant- level between various sarcopenia definitions. Our findings suggest that the concept of sarcopenia may need to be rethought to reliably and validly identify people with impaired muscle health.

摘要

目的

关于一般健康老年人肌少症的多国患病率数据有限。本研究的目的是基于 12 种现行肌少症定义,评估 DO-HEALTH 欧洲试验中的肌少症患病率。

设置和参与者

这是 DO-HEALTH 研究的一项分析,纳入了来自德国、法国、葡萄牙和瑞士的 2157 名社区居住的 70 岁以上参与者中的 1495 名,这些参与者完成了肌少症工具箱的完整测量,包括使用 DXA 测量肌肉质量、握力和步速。

测量方法

应用的 12 种肌少症定义包括亚洲肌少症工作组(AWGS1)、AWGS2、Baumgartner、Delmonico、欧洲老年人肌少症工作组(EWGSOP1)、EWGSOP2、EWGSOP2-下肢、美国国立卫生研究院基金会(FNIH1)、FNIH2、国际老年人肌少症工作组(IWGS)、Morley 和肌少症定义和结果联合会(SDOC)。

结果

平均年龄为 74.9 岁(SD 4.4);63.3%为女性。使用 EWGSOP2 或 AWGS2 定义,肌少症患病率在 0.7%之间,使用 Delmonico 定义,肌少症患病率高达 16.8%。总体而言,大多数肌少症定义,包括 Delmonico(16.8%)、Baumgartner(12.8%)、FNIH1(10.5%)、IWGS(3.6%)、EWGSOP1(3.4%)、SDOC(2.0%)、Morley(1.3%)和 AWGS1(1.1%),均高于基于 EWGSOP2(0.7%)的患病率。相比之下,基于肌肉质量和肌肉力量的定义 AWGS2(0.7%)、EWGSOP2-LE(1.1%)和 FNIH2(1.0%)的患病率则相似,均为 EWGSOP2(0.7%)。此外,在个体参与者层面上,大多数肌少症定义并未对肌少症进行重叠识别。

结论

在这项针对社区居住的老年人的欧洲多国试验中,我们发现,在人群层面和个体参与者层面上,不同肌少症定义之间的肌少症患病率存在很大差异。我们的研究结果表明,肌少症的概念可能需要重新考虑,以可靠和有效地识别肌肉健康受损的人群。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验